Irinotecan is an active agent in untreated patients with metastatic colorectal cancer.
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
PURPOSE: To determine the response rate, survival, and toxicity of the new anticancer agent, irinotecan (CPT-11), in the treatment of metastatic colorectal cancer. PATIENTS AND METHODS: Forty-one chemotherapy-naive patients with measurable metastatic colorectal cancer were treated with a 90-minute infusion of irinotecan 125 mg/m2 administered weekly for 4 weeks every 6 weeks. Pretreatment tumor biopsies to assess topoisomerase-I (Topo-I) activity were obtained from 11 patients. The pharmacokinetics for irinotecan and its active metabolite, SN-38, were determined in 18 patients. RESULTS: Thirteen of 41 patients (32%) had a partial response (PR; 95% confidence interval, 18% to 46%). The median response duration was 8.1 months (range, 4.0 to 16.0) and the median survival time was 12.1 months (range, 2.1 to 21.7) for all 41 patients. Grade 3 or 4 toxicities were diarrhea (29% of patients) and neutropenia (22% of patients). Grade 3 or 4 diarrhea was substantially more prevalent in the initial 18 patients on study, with an incidence rate of 56%; a significant reduction in the incidence of severe diarrhea to 9% was noted with strict adherence to an antidiarrheal regimen of loperamide and diphenyldramine. No correlations were seen between pharmacokinetics of irinotecan/SN-38 and the clinical parameters of response, survival, or incidence of diarrhea. CONCLUSIONS: Irinotecan has activity in the treatment of patients with metastatic colorectal cancer. Strict adherence to an antidiarrheal regimen of diphenhydramine/loperamide significantly reduced the incidence of diarrhea; the agent was thereafter well tolerated in the majority of patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Wall, M. E., Wani, M. C., Cook, C. E., Palmer, K. H., McPhail, A. T., & Sim, G. A. (1966) · Journal of the American Chemical Society · doi:10.1021/ja00968a057 · Cited by 2,258
(1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.6.896 · Cited by 1,189
Hsiang, Y. H., Lihou, M. G., & Liu, L. F. (1989) · PubMed · Cited by 1,028
Kawato, Y., Aonuma, M., Hirota, Y., Kuga, H., & Sato, K. (1991) · PubMed · Cited by 865
DNA Topoisomerase I—Targeted Chemotherapy of Human Colon Cancer in Xenografts
Giovanella, B. C., Stehlin, J. S., Wall, M. E., Wani, M. C., Nicholas, A. W., Liu, L. F., Silber, R., & Potmesil, M. (1989) · Science · doi:10.1126/science.2555920 · Cited by 650
The Current Status of Camptothecin Analogues as Antitumor Agents
Slichenmyer, W. J., Rowinsky, E. K., Donehower, R. C., & Kaufmann, S. H. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.4.271 · Cited by 618
Kunimoto, T., Nitta, K., Tanaka, T., Uehara, N., Baba, H., Takeuchi, M., YOKOKURA, T., Sawada, S., Miyasaka, T., & Mutai, M. (1987) · PubMed · Cited by 410
Eukaryotic DNA topoisomerases: two forms of type I DNA topoisomerases from HeLa cell nuclei.
Liu, L. F., & Miller, K. G. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.6.3487 · Cited by 346
Abigerges, D., Chabot, G. G., Armand, J. P., Hérait, P., Gouyette, A., & Gandia, D. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.1.210 · Cited by 299
Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer.
Moertel, C. G., Schutt, A. J., Reitemeier, R. J., et al. (1972) · PubMed · Cited by 274
Irinotecan (CPT-11) High-Dose Escalation Using Intensive High-Dose Loperamide to Control Diarrhea
Abigerges, D., Armand, J.-P., Chabot, G. G., Costa, L. D., Fadel, E., Cote, C., Herait, P., & Gandia, D. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.6.446 · Cited by 248
Sugimoto, Y., Tsukahara, S., Oh‐hara, T., Isoe, T., & TSURUO, T. (1990) · PubMed · Cited by 223
Cellular Determinants of Sensitivity and Resistance to DNA Topoisomerase Inhibitors
Pommier, Y., Pharm, D., Fesen, M. R., Fujimori, A., Bertrand, R., Solary, E., Kohlhagen, G., & Kohn, K. W. (1994) · Cancer Investigation · doi:10.3109/07357909409021413 · Cited by 207
Rowinsky, E. K., Grochow, L. B., Ettinger, D. S., Sartorius, S. E., Lubejko, B. G., Chen, T. L., Rock, M. K., & Donehower, R. C. (1994) · PubMed · Cited by 194
DNA Topoisomerases as Anticancer Drug Targets
Schneider, E., Hsiang, Y.-H., & Liu, L. F. (1990) · Advances in Pharmacology · doi:10.1016/s1054-3589(08)60342-7 · Cited by 193
Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice
Kawato, Y., Furuta, T., Aonuma, M., Yasuoka, M., Yokokura, T., & Matsumoto, K. (1991) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00685508 · Cited by 159
Goldwasser, F., Bae, I., Valenti, M. R., Torres, K. E., & Pommier, Y. G. (1995) · PubMed · Cited by 155
Prognostic factors in advanced colorectal carcinoma
Kemeny, N. E., & Braun, D. W. (1983) · The American Journal of Medicine · doi:10.1016/0002-9343(83)91066-5 · Cited by 145
Self-citationCharacterization of a camptothecin-resistant human DNA topoisomerase I.
Kjeldsen, E., Bonven, B. J., Andoh, T., Ishii, K., Okada, K., Bolund, L., & Westergaard, O. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)69012-x · Cited by 82
Sasaki, Y., Yoshida, Y., Sudoh, K., Hakusui, H., Fujii, H., Ohtsu, T., Wakita, H., Igarashi, T., & Itoh, K. (1995) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1995.tb02995.x · Cited by 58
Systemic Therapy in Metastatic Colorectal Cancer
Hansen, R. M. (1990) · Archives of Internal Medicine · doi:10.1001/archinte.1990.00390220027007 · Cited by 23
[Effect of chemotherapy using irinotecan (CPT-11) against recurrent colorectal cancer].
Nishimura, G., Satou, T., Yoshimitsu, Y., Kurosaka, Y., Fujimura, T., Sugiyama, K., Kanno, M., Yonemura, Y., Miwa, K., & Miyazaki, I. (1995) · PubMed · Cited by 13
Cited by
Chou, T.-C. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.10 · Cited by 5,163
Self-citationIrinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
Self-citationRecommended Guidelines for the Treatment of Cancer Treatment-Induced Diarrhea
Benson, A. B., Ajani, J. A., Catalano, R. B., Engelking, C., Kornblau, S. M., Martenson, J. A., McCallum, R., Mitchell, E. P., O'Dorisio, T. M., Vokes, E. E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.132 · Cited by 631
Cancer Therapies Utilizing the Camptothecins: A Review of the in Vivo Literature
Venditto, V. J., & Simanek, E. E. (2010) · Molecular Pharmaceutics · doi:10.1021/mp900243b · Cited by 452
Saltz, L. B., Niedzwiecki, D., Hollis, D., Goldberg, R. M., Hantel, A., Thomas, J. P., Fields, A. L. A., & Mayer, R. J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.2144 · Cited by 449
Self-citation
Metadata
- Authors
- Conti, J. A., Kemeny, N. E., Saltz, L. B., Huang, Y., Tong, W. P., Chou, T. C., Sun, M., Pulliam, S., & Gonzalez, C.
- Venue
- Journal of Clinical Oncology
- Published
- 1996-03
- Volume
- 14
- Issue
- 3
- Pages
- 709-715
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1952371628
- Cited by
- 344
- References
- 24
- FWCI
- 11.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.